Trial
NCT02737202
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Baylor College of Medicine
Collaborators
University of Cincinnati; Brigham and Women's Hospital; Stanford University; Loyola University; University of South Florida; National Institutes of Health (NIH)
Condition
Pulmonary Lymphangioleiomyomatosis
Intervention
saracatinib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-30